All In Biotech

BLA 761043 · Glaxosmithkline LLC

Benlysta

Belimumab · Injection · B Lymphocyte Stimulator-specific Inhibitor

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Jul 20, 2017

Approved uses

5

Original approval plus efficacy supplements

Registered trials

86

20 Phase 3, 18 recruiting

FAERS reports

32,030

13,657 serious, 907 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 30, 2026.

BENLYSTA is indicated for the treatment of patients 5 years of age and older with: • Active systemic lupus erythematosus (SLE) who are receiving standard therapy, and • Active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system (CNS) lupus. Use of BENLYSTA is not recommended in this situation. BENLYSTA is a B-lymphocyte stimulator (BLyS)-specific inhibitor indicated for the treatment of patients 5 years of age and older with: • Active systemic lupus erythematosus (SLE) who are receiving standard therapy; ( 1 ) • Active lupus nephritis who are receiving standard therapy. ( 1 ) Limitations of Use: The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system lupus. Use of BENLYSTA is not recommended in this situation. ( 1 )

Mechanism: BENLYSTA is a BLyS-specific inhibitor that blocks the binding of soluble BLyS, a B-cell survival factor, to its receptors on B cells. BENLYSTA does not bind B cells directly, but by binding BLyS, BENLYSTA inhibits the survival of B cells, including autoreactive B cells, and reduces the differentiation of B cells into immunoglobulin-producing plasma cells.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • BENLYSTA · BELIMUMAB 200MG/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Belimumab" as an intervention, any sponsor and status, largest first.

All 86 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue5,154
  • systemic lupus erythematosus3,979
  • fatigue2,095
  • drug ineffective1,857
  • pain1,776
  • wrong technique in device usage process1,635
  • headache1,593
  • nausea1,526
  • malaise1,425
  • product complaint1,411
  • injection site pain1,388
  • arthralgia1,380

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2011132
2012893
2013711
2014656
20151,107
2016802
20171,033
20182,166
20192,969
20202,195
20212,402
20222,867
20233,400
20243,817
20255,198
20261,682

Recalls

1 FDA enforcement reports for this application.

  • Apr 21, 2025 · Class II · Ongoing

    CGMP Deviations; potential temperature excursions due to transit delays

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Benlysta* (Belimumab)

2024 spending

$217M

Beneficiaries

5,831

44,771 claims

Per beneficiary

$37,182

$1,204.92 per unit

View as table
YearSpending
2020$96,759,690
2021$121,887,629
2022$149,755,010
2023$187,011,628
2024$216,806,704

Part B: Benlysta (Belimumab) · HCPCS J0490

2024 spending

$126M

Beneficiaries

3,685

30,420 claims

Per beneficiary

$34,064

2024 ASP limit $53.59 per unit

View as table
YearSpending
2020$93,003,577
2021$102,382,337
2022$112,789,686
2023$117,883,242
2024$125,525,139

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 187 on PubMed

Sponsor: GSK

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.